MS

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Retrieved on: 
Wednesday, November 1, 2023

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Key Points: 
  • BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company’s growth and partnering activities, including value creation through collaborations with large pharmaceutical and biotech partners.
  • Ms. Krebs holds an MS in biotechnology from Johns Hopkins University and an MBA from the University of Rochester.
  • “We’re delighted to welcome Stephanie to our leadership team at such an exciting moment for Sensei, as we advance the ongoing Phase 1/2 clinical trial of our lead candidate SNS-101 and prepare to move an additional candidate toward IND-enabling studies,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics.

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Retrieved on: 
Wednesday, November 1, 2023

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • Key findings showed that NLRP3 inflammasome inhibition:
    Ameliorated pathological changes in the spinal cord and neuron damage in the brain of MS mice.
  • “It is encouraging that the research published in Molecular Neurobiology substantiates our published MS data with Inflammasome ASC Inhibitor IC 100, providing support for its use as a potential therapeutic option.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

Retrieved on: 
Monday, October 30, 2023

Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.

Key Points: 
  • INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).
  • The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP.
  • INB03 downregulates SIRPα expression to eliminate the “don’t eat me signal” and promote ADCP.
  • INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression.

Dayna Timmer, PharmD, Receives the 2023 George Roentsch, RPh, New Innovator Award from PCCA

Retrieved on: 
Friday, October 27, 2023

Houston, Texas, Oct. 27, 2023 (GLOBE NEWSWIRE) -- PCCA has named Dayna Timmer, PharmD, owner of Mountainside Compounding in Tate, Georgia, as the recipient of the 2023 George Roentsch, RPh, New Innovator Award.

Key Points: 
  • Houston, Texas, Oct. 27, 2023 (GLOBE NEWSWIRE) -- PCCA has named Dayna Timmer, PharmD, owner of Mountainside Compounding in Tate, Georgia, as the recipient of the 2023 George Roentsch, RPh, New Innovator Award.
  • PCCA Director of Member Engagement Erin Michael, MBA, MS, CPhT, FAPC, presented the award to Timmer on Friday, October 27, during PCCA’s ThinkNext: International Seminar 2023, in Houston, Texas.
  • Established in 2010, this award is given annually to an up-and-coming independent pharmacist and PCCA member who embodies the innovative and sharing nature for which George Roentsch was well-known in the pharmacy compounding community.
  • “Dayna truly exemplifies the innovative and passionate spirit of George,” Michael said.

$31.4 Billion In-vehicle Infotainment Markets - Global Forecast to 2028: 5G and Ai Revolutionizing Seamless Entertainment on the Go - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023

Second, government regulations and mandates related to vehicle safety and connectivity are driving the adoption of in-vehicle infotainment systems.

Key Points: 
  • Second, government regulations and mandates related to vehicle safety and connectivity are driving the adoption of in-vehicle infotainment systems.
  • During the forecast period, the infotainment unit is expected to lead the in-vehicle infotainment market under the components segment.
  • Nowadays new SUVs are incomplete without an all-encompassing infotainment system, the demand for SUVs is rising, hence rising the in-vehicle infotainment system market.
  • The emergence of 5G is also expected to contribute to developing the in-vehicle infotainment market.

Entegris Reports Results for Third Quarter of 2023

Retrieved on: 
Thursday, November 2, 2023

Excluding the sales of these divested businesses for the third quarter 2023, fourth quarter 2023 sales are estimated to be down sequentially approximately 2% at the midpoint of the fourth quarter 2023 sales guidance range provided below.

Key Points: 
  • Excluding the sales of these divested businesses for the third quarter 2023, fourth quarter 2023 sales are estimated to be down sequentially approximately 2% at the midpoint of the fourth quarter 2023 sales guidance range provided below.
  • The Company also expects EBITDA of approximately 26% to 27% of sales, for the fourth quarter of 2023.
  • Entegris will hold a conference call to discuss its results for the third quarter on Thursday, November 2, 2023, at 9:00 a.m. Eastern Time.
  • Management’s slide presentation concerning the results for the third quarter will be posted on the Investor Relations section of www.entegris.com in the morning before the call.

Pharmacy Benefit Managers Expose Patients to Negative Health Outcomes, GHLF Updated Studies Shows

Retrieved on: 
Thursday, November 2, 2023

The updated research found that more than half the exclusions (57%) had questionable medical or economic benefits for patients.

Key Points: 
  • The updated research found that more than half the exclusions (57%) had questionable medical or economic benefits for patients.
  • The original peer-reviewed research and its update, which is not yet published, focuses on ESI, the second largest pharmacy benefit manager in the United States.
  • This forced switch to different medications also adds to the challenges patients and their caregivers face, and it ends up costing more for everyone involved in health care — patients, caregivers, employers, and the government.
  • GHLF will host a webinar concerning formulary exclusions and their impact on patients on November 9 at 12 pm EST.

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

Retrieved on: 
Thursday, November 2, 2023

After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.

Key Points: 
  • After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.
  • To develop the AI models, GE HealthCare and VUMC retrospectively analyzed and correlated the immunotherapy treatment response of thousands of VUMC cancer patients, with their deidentified demographic, genomic, tumor, cellular, proteomic, and imaging data.
  • “These results are a promising development in the journey towards precision care, selecting treatment pathways based on the individual patient’s likely response.
  • The AI models are an integral part of GE HealthCare’s immuno-oncology development portfolio which includes the development of novel PET tracers.

ICP MS System Market to Cross USD 599.4 million by 2031, Garnering a 4.6% CAGR from 2023 to 2031: TMR Report

Retrieved on: 
Monday, November 6, 2023

WILMINGTON, Del., Nov. 6, 2023 /PRNewswire/ -- The global ICP MS system market was estimated to have acquired US$ 391.3 million in 2022. It is anticipated to register a 4.6% CAGR from 2023 to 2031 and by 2031, the market is likely to gain US$ 599.4 million.  

Key Points: 
  • By Application, the pharmaceutical and biomedical research segment is expected to accelerate the demand for ICP MS system.
  • ICP MS systems are employed in clinical and medical research for analyzing biomarkers, heavy metal poisoning, and trace element diagnostics, which has created a new market segment for ICP MS.
  • Global Market for ICP MS System: Regional Outlook
    Various reasons are propelling the growth of the ICP MS System market in different regions.
  • Global ICP MS System Market: Key Players
    The following companies are well known participants in the global ICP MS system market:
    Advion Inc. (Beijing Bohui Innovation Biotechnology Co., Ltd.)

ICP MS System Market to Cross USD 599.4 million by 2031, Garnering a 4.6% CAGR from 2023 to 2031: TMR Report

Retrieved on: 
Monday, November 6, 2023

WILMINGTON, Del., Nov. 6, 2023 /PRNewswire/ -- The global ICP MS system market was estimated to have acquired US$ 391.3 million in 2022. It is anticipated to register a 4.6% CAGR from 2023 to 2031 and by 2031, the market is likely to gain US$ 599.4 million.  

Key Points: 
  • By Application, the pharmaceutical and biomedical research segment is expected to accelerate the demand for ICP MS system.
  • ICP MS systems are employed in clinical and medical research for analyzing biomarkers, heavy metal poisoning, and trace element diagnostics, which has created a new market segment for ICP MS.
  • Global Market for ICP MS System: Regional Outlook
    Various reasons are propelling the growth of the ICP MS System market in different regions.
  • Global ICP MS System Market: Key Players
    The following companies are well known participants in the global ICP MS system market:
    Advion Inc. (Beijing Bohui Innovation Biotechnology Co., Ltd.)